Mind Med | Company Profile
NEO : MMED, NASDAQ : MNMD
Latest Sector Updates
Mindmed is focusing on solving the growing incidence of mental health conditions through clinical trials of psychedelic inspired medicines and therapies. They are seeking to apply psychedelics to a range of mental health problems including anxiety, ADHD, cluster headaches and addiction. Their clinical trials include LSD experiential therapy for anxiety, psychedelic inspired medicine to treat addiction and microdosing LSD to treat ADHD.
In March 2021 they announced a C$19.5m bought deal private placement offering.
In April 2021 Mindmed completed a successful listing on the NASDAQ exchange in New York under the ticker MNMD.
Stock information
Latest MindMed News
MindMed to Present at Web Summit on Future of Mental Health
NEW YORK , Nov. 1, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to ...
MindMed CMO to Chair Digital Biomarkers Summit
NEW YORK , Oct. 25, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased ...
MindMed Joins Clinical Trials Transformation Initiative
NEW YORK , Oct. 13, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has joined ...
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK , Oct. 5, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has agreed ...
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
NEW YORK , Sept. 30, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (“MindMed” or the “Company”), a leading biotech company developing psychedelic-inspired ...
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
NEW YORK , Sept. 29, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is ...
